Parkinson’s disease

October 18, 2012

Nobel in Chemistry reveals VU ties that bind

Several Vanderbilt researchers have collaborated with this year’s Nobel Chemistry winners.

By Bill Snyder
September 21, 2012

VU, Bristol-Myers to collaborate on Parkinson’s therapies

Vanderbilt University and Bristol-Myers Squibb have signed a collaboration agreement for the discovery, development and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive allosteric modulators, or PAMs, for the treatment of Parkinson’s disease.

By Bill Snyder
September 7, 2012

Parkinson’s therapy may impact language

Deep brain stimulation used to treat Parkinson’s disease may impair some aspects of language processing, a recent study suggests.

By VUMC News and Communications
August 23, 2012

Events honor early patients of novel Parkinson’s study

Pioneers of Parkinson’s disease research are gathering at Vanderbilt University Medical Center today to celebrate the end of a study that was an important first step in the quest to find a way to slow the progression of the degenerative movement disorder.

By VUMC News and Communications
Brain and doorway concept
April 6, 2012

Minds wide open: Neuroscience at Vanderbilt

Vanderbilt University has emerged as one of the nation’s leading academic centers in neuroscience.

By Bill Snyder
brain
October 5, 2011

Parkinson’s deep brain target fired up

Neuronal activity in a deep brain region increases as Parkinson’s disease advances, a new study suggests.

By Leigh MacMillan
October 3, 2011

Researchers strive to refill drug discovery ‘pipeline’

By Bill Snyder
September 30, 2011

Drug-like molecules aimed at improving treatment of Parkinson’s

Drug-like molecules described by Vanderbilt researchers could lead to Parkinson's treatments with fewer side effects.
By Bill Snyder
March 11, 2011

Neuroscience drug discovery center opens at Vanderbilt

Vanderbilt University Medical Center has established a new Center for Neuroscience Drug Discovery to accelerate research that may lead to new treatments for Parkinson's disease, schizophrenia and other disorders of the brain.
By Bill Snyder
1 2 3